Effect of renin–angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial

Abstract

AbstractIntroductionThe clinical benefits of renin–angiotensin system inhibitors (RASi) in patients undergoing hemodialysis remain obscure.MethodsThis is a post hoc cohort analysis of the LANDMARK trial investigate whether RASi use was associated with cardiovascular events (CVEs) and all‐cause mortality. A total of 2135 patients at risk for vascular calcification were analyzed using a Cox proportional hazards model with propensity‐score matching.ResultsThe risk of CVEs was similar between participants with RASi use at baseline and those without RASi use at baseline and between participants with RASi use during the study period and those without RASi use during the study period. No clinical benefits of RASi use on all‐cause mortality were observed. Serum phosphate levels were significantly associated with the effect of RASi on CVEs.ConclusionsRASi use was not significantly associated with a lower risk of CVEs or all‐cause mortality in hemodialysis patients at risk of vascular calcification.